Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CONy 2023 | GFAP and NfL as biomarkers in NMOSD

Celia Oreja-Guevara, MD, PhD, University Hospital San Carlos, Madrid, Spain, discusses the utility of biomarkers of astrocytic and neuronal damage for monitoring neuromyelitis optica spectrum disorder (NMOSD) disease activity and guiding changes in treatment. Studies have shown that glial fibrillary acidic protein (GFAP) increases months before relapses, suggesting that it could be used as a prognostic marker. GFAP is very well correlated with acute disease activity, progression, and treatment response, as shown by studies with inebilizumab and rituximab. The utility of neurofilament light chain (NfL) in NMOSD is unclear, and evidence indicates that the marker will probably need to be combined with other biomarkers. This interview took place at the 17th World Congress on Controversies in Neurology (CONy) in Dubrovnik, Croatia.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.